Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Context builds bispecific bank with $133M biobucks deal
For further context, the antibody binds to Nectin-4 on tumor cells and CD3 on T cells, galvanizing the T cells to attack the cancer.
Darren Incorvaia
Sep 23, 2024 11:20am
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet
Sep 16, 2024 6:59am
ESMO: Regeneron's Opdualag rival shows 57% response rate
Sep 14, 2024 3:00am
ESMO: AstraZeneca posts data on ADC rivals to AbbVie, Pfizer
Sep 14, 2024 3:00am
ArsenalBio raises $325M, pivots away from former lead asset
Sep 4, 2024 8:00am
Repare lays off 25% of staff as biotech halts preclinical R&D
Aug 29, 2024 6:36am